GTS Securities’s Allogene Therapeutics ALLO Stock Holding History

GTS Securities’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,994	Closed	-$34.9K	–	4007
2023 Q3	$34.9K	Buy	+10,994	New	+$48.2K	﹤0.01%	3751

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

GTS Securities's ALLO Position: Q4 2023 in Review

GTS Securities sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 10,994 shares — an estimated $34.9K sold.

GTS Securities first reported a position in ALLO in Q3 2023 and held it in 1 quarter. The position peaked at $34.9K in Q3 2023. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

GTS Securities reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 10,994 Allogene Therapeutics shares in Q4 2023, an estimated $34.9K.
GTS Securities first reported a position in Allogene Therapeutics in Q3 2023 and held it in 1 quarter.
GTS Securities's Allogene Therapeutics position peaked at $34.9K in Q3 2023.
170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.